Federica Sella

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 5

Top Topics

Ulcerative Colitis

Top Venues

EMBO molecular medicine

Cancer research

Communications biology

This page only lists publications with an associated author ORCID identifier.

Publications

Sarah Proteau, Imène Krossa, Chrystel Husser, Maxime Guéguinou, Federica Sella, Karine Bille, Marie Irondelle, Mélanie Dalmasso, Thibault Barouillet, Yann Cheli, Céline Pisibon, Nicole Arrighi, Sacha Nahon-Estève, Arnaud Martel, Lauris Gastaud, Sandra Lassalle, Olivier Mignen, Patrick Brest, Nathalie M Mazure, Frédéric Bost, Stéphanie Baillif, Solange Landreville, Simon Turcotte, Dan Hasson, Saul Carcamo, Christophe Vandier, Emily Bernstein, Laurent Yvan-Charvet, Mitchell P Levesque, Robert Ballotti, Corine Bertolotto, Thomas Strub
Publisher Correction: LKB1-SIK2 loss drives uveal melanoma proliferation and hypersensitivity to SLC8A1 and ROS inhibition. EMBO molecular medicine (2024)
Florentia Dimitriou, Phil Fang Cheng, Annalisa Saltari, Katrin Schaper-Gerhardt, Ramon Staeger, Veronika Haunerdinger, Federica Sella, Aizhan Tastanova, Christian Urban, Susanne Dettwiler, Daniela Mihic-Probst, Christian M Matter, Olivier Michielin, Ralf Gutzmer, Georgina V Long, Burkhard Becher, Mitchell Paul Levesque, Reinhard Dummer
A targetable type III immune response with increase of IL-17A expressing CD4 + T cells is associated with immunotherapy-induced toxicity in melanoma. Nature cancer (2024)
Ulrike Lischetti, Aizhan Tastanova, Franziska Singer, Linda Grob, Matteo Carrara, Phil F Cheng, Julia M Martínez Gómez, Federica Sella, Veronika Haunerdinger, Christian Beisel, Mitchell Paul Levesque
Dynamic thresholding and tissue dissociation optimization for CITE-seq identifies differential surface protein abundance in metastatic melanoma. Communications biology 6 (1) (2023)
Sarah Proteau, Imène Krossa, Chrystel Husser, Maxime Guéguinou, Federica Sella, Karine Bille, Marie Irondelle, Mélanie Dalmasso, Thibault Barouillet, Yann Cheli, Céline Pisibon, Nicole Arrighi, Sacha Nahon-Estève, Arnaud Martel, Lauris Gastaud, Sandra Lassalle, Olivier Mignen, Patrick Brest, Nathalie M Mazure, Frédéric Bost, Stéphanie Baillif, Solange Landreville, Simon Turcotte, Dan Hasson, Saul Carcamo, Christophe Vandier, Emily Bernstein, Laurent Yvan-Charvet, Mitchell Paul Levesque, Robert Ballotti, Corine Bertolotto, Thomas Strub
LKB1-SIK2 loss drives uveal melanoma proliferation and hypersensitivity to SLC8A1 and ROS inhibition. EMBO molecular medicine (2023)
Lorenza P Ferretti, Flurina Böhi, Deena M Leslie Pedrioli, Phil Fang Cheng, Elena Ferrari, Petra Baumgaertner, Abdiel Alvarado-Diaz, Federica Sella, Alessandra Cereghetti, Patrick Turko, Roni H G Wright, Katrien De Bock, Daniel E Speiser, Roberto Ferrari, Mitchell Paul Levesque, Michael O Hottiger
Combinatorial treatment with PARP and MAPK inhibitors overcomes phenotype switch-driven drug resistance in advanced melanoma. Cancer research (2023)